Boardroom Alpha
Meeting calendar
TEM · Annual meeting · Thursday, May 21, 2026

Tempus Ai Inc

9 nominees · 3 ballot items.

Stockholders will vote to elect nine directors, ratify PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the 2026 fiscal year, and cast a non-binding advisory vote on the frequency (one, two or three years) of future say-on-pay votes (the Board recommends a three-year frequency).

Market cap
$10.3B
1Y TSR
-7.3%
Board grade
C-
Record date
Mar 27, 2026
Filing
DEF 14A
Meeting concluded · May 21, 2026

Follow how the vote landed and what changed on Tempus Ai Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot3

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect nine directors nominated by the Board to serve until the next annual meeting and their successors.

  2. 2

    Ratification of Appointment of Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    Ratify the Audit Committee’s appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

  3. 3

    Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation

    ManagementBoard: FOR

    Non-binding advisory vote to indicate whether future advisory votes to approve executive compensation (say-on-pay) should occur every one, two, or three years (Board recommends three years).

    More detail

    This advisory proposal asks stockholders to indicate, on a non-binding basis, whether the Company should hold future advisory votes to approve executive compensation every one, two, or three years (the "say-on-frequency" choice that will determine how often the Board solicits a say-on-pay vote). Management explains that the first binding-style say-on-pay vote will occur in 2027 and stresses that the outcome of this advisory frequency vote is non-binding, though the Board and the Compensation Committee will carefully consider the results in setting future practice. The Board recommends a triennial (three-year) frequency, arguing it is the most appropriate balance between meaningful shareholder input and allowing time for the Company’s long-term compensation programs—particularly performance-based, multi-year equity awards—to mature and produce measurable outcomes. A three-year vote cadence aligns with the Company’s use of multi-year performance-based RSUs (PSUs) tied to multi-year revenue growth and relative TSR metrics, reducing the risk that short-term fluctuations drive compensation decisions. For governance-focused investors, a triennial recommendation may be seen as limiting immediate accountability compared with annual votes; however, management underscores that the vote remains advisory and the Board will consider stockholder sentiment. The Committee’s deference to a three-year cycle likely reflects an intent to reduce administrative and engagement costs and to provide stability and predictability for long-term incentive design, while still retaining responsiveness to major shareholder concerns. If stockholders prefer more frequent input, they can vote for one- or two-year frequencies; the Board has committed to give weight to the prevailing stockholder preference even though it is not legally bound. In evaluating the proposal, analysts should weigh the Company’s governance posture, the structure of its 2025 PSUs and RSUs, and recent shareholder returns and engagement history to assess whether a triennial cadence appropriately balances accountability and long-term incentive effectiveness.

Director elections

Nominees on the ballot9

Independent
Tenure on this board
8.9 yrs
Also a director at
Sprout Social Inc (SPT)
Independent
Tenure on this board
2.5 yrs
Also a director at
Agomab Therapeutics NV (AGMB)
Independent
Tenure on this board
5.8 yrs
Also a director at
Humana Inc (HUM)Insulet Corp (PODD)Workday Inc (WDAY)
Independent
Tenure on this board
6.8 yrs
Also a director at
Pfizer Inc (PFE)Illumina Inc (ILMN)Unitedhealth Group Inc (UNH)
Independent
Tenure on this board
7.5 yrs
Also a director at
Groupon Inc (GRPN)American Express Co (AXP)
Independent
Tenure on this board
5.3 yrs
Also a director at
Nucor Corp (NUE)Tenet Healthcare Corp (THC)Johnson & Johnson (JNJ)
Ownership

Top institutional holders10

Latest 13F quarter
1ARK Investment Management LLC5.4%9,607,745$434M
2GC Wealth Management RIA, LLC3.7%6,611,211$299M
3SOFTBANK GROUP CORP.3.0%5,405,406$244M
4BAILLIE GIFFORD CO3.0%5,331,864$241M
5VANGUARD CAPITAL MANAGEMENT LLC2.7%4,918,122$222M
6VANGUARD PORTFOLIO MANAGEMENT LLC2.6%4,679,057$212M
7BlackRock, Inc.2.5%4,575,375$207M
8Amova Asset Management Americas, Inc.2.4%4,326,313$196M
9Sumitomo Mitsui Trust Group, Inc.2.4%4,326,313$196M
10UBS Group AG1.5%2,768,551$125M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Tempus Ai Inc 2026 annual meeting?
Tempus Ai Inc (TEM) holds its 2026 annual shareholder meeting on Thursday, May 21, 2026.
What is the record date for the Tempus Ai Inc 2026 meeting?
The record date for the Tempus Ai Inc 2026 meeting is Friday, March 27, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Tempus Ai Inc's 2026 meeting?
The board is presenting 9 director nominees at the Tempus Ai Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Tempus Ai Inc 2026 meeting?
Shareholders will vote on 3 proposals at the Tempus Ai Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer